Sectoral Asset Management

Total investments

54

Average round size

58M

Portfolio companies

37

Rounds per year

2.25

Lead investments

8

Follow on index

0.31

Exits

15

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Sectoral Asset Management appeared to be the Corporate Investor, which was created in 2000. The leading representative office of defined Corporate Investor is situated in the Montru00e9al. The venture was found in North America in Canada.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Sectoral Asset Management, startups are often financed by HealthCap, Astellas Venture Management, Ysios Capital. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Andera Partners, Versant Ventures. In the next rounds fund is usually obtained by T. Rowe Price, Ysios Capital, Venrock.

Among the most popular portfolio startups of the fund, we may highlight F2G, BioVex, HighLife. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Personal Health, Medical Device.

This organization was formed by Franklin Berger, Jerome Pfund, Michael Sjostrom. The overall number of key employees were 4.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Sectoral Asset Management works on 12 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2015. The real fund results show that this Corporate Investor is 6 percentage points less often commits exit comparing to other companies. The higher amount of exits for fund were in 2019.

Show more

Investments analytics

Analytics

Total investments
54
Lead investments
8
Exits
15
Rounds per year
2.25
Follow on index
0.31
Investments by industry
  • Health Care (37)
  • Biotechnology (32)
  • Medical (28)
  • Therapeutics (20)
  • Medical Device (19)
  • Show 16 more
Investments by region
  • United States (41)
  • United Kingdom (5)
  • France (3)
  • Switzerland (3)
  • Sweden (2)
Peak activity year
2021
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
79M
Group Appearance index
0.96
Avg. company exit year
10
Avg. multiplicator
2.77
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Cagent Vascular 20 Feb 2024 Medical Device Late Stage Venture 30M United States, Pennsylvania, Radnor Township
Mineralys Therapeutics 08 Jun 2022 Biotechnology, Medical, Pharmaceutical, Biopharma Early Stage Venture 118M United States, Radnor, Pennsylvania

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.